[go: up one dir, main page]

HRP20020206B1 - Solid lipid formulations - Google Patents

Solid lipid formulations

Info

Publication number
HRP20020206B1
HRP20020206B1 HR20020206A HRP20020206A HRP20020206B1 HR P20020206 B1 HRP20020206 B1 HR P20020206B1 HR 20020206 A HR20020206 A HR 20020206A HR P20020206 A HRP20020206 A HR P20020206A HR P20020206 B1 HRP20020206 B1 HR P20020206B1
Authority
HR
Croatia
Prior art keywords
solid lipid
lipid formulations
fatty acid
acid ester
composition
Prior art date
Application number
HR20020206A
Other languages
English (en)
Croatian (hr)
Inventor
Christiaan De Smidt Passchier
Hadvary Paul
Lengsfeld Hans
Schmid Marcel
Macfarland Small David
Steffen Hans
Tardio Joseph
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20020206(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20020206A2 publication Critical patent/HRP20020206A2/xx
Publication of HRP20020206B1 publication Critical patent/HRP20020206B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
HR20020206A 1999-09-13 2000-09-11 Solid lipid formulations HRP20020206B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99118179 1999-09-13
PCT/EP2000/008857 WO2001019378A2 (en) 1999-09-13 2000-09-11 Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols

Publications (2)

Publication Number Publication Date
HRP20020206A2 HRP20020206A2 (en) 2004-04-30
HRP20020206B1 true HRP20020206B1 (en) 2011-02-28

Family

ID=8238989

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020206A HRP20020206B1 (en) 1999-09-13 2000-09-11 Solid lipid formulations

Country Status (36)

Country Link
US (1) US6703369B1 (xx)
EP (1) EP1216048B1 (xx)
JP (1) JP4217017B2 (xx)
KR (1) KR100523879B1 (xx)
CN (1) CN1197554C (xx)
AR (1) AR025609A1 (xx)
AT (1) ATE285783T1 (xx)
AU (1) AU769016B2 (xx)
BR (1) BRPI0013940B1 (xx)
CA (1) CA2383036C (xx)
CO (1) CO5210857A1 (xx)
CZ (1) CZ301844B6 (xx)
DE (1) DE60017156T2 (xx)
EG (1) EG24225A (xx)
ES (1) ES2233444T3 (xx)
GC (1) GC0000259A (xx)
HK (1) HK1049798B (xx)
HR (1) HRP20020206B1 (xx)
HU (1) HU229037B1 (xx)
IL (2) IL148570A0 (xx)
JO (1) JO2300B1 (xx)
MA (1) MA26817A1 (xx)
ME (1) ME00675B (xx)
MX (1) MXPA02002662A (xx)
MY (1) MY127430A (xx)
NO (1) NO328889B1 (xx)
NZ (1) NZ517396A (xx)
PE (1) PE20010661A1 (xx)
PL (1) PL199869B1 (xx)
PT (1) PT1216048E (xx)
RS (1) RS50373B (xx)
RU (1) RU2248218C2 (xx)
SI (1) SI1216048T1 (xx)
TR (1) TR200200605T2 (xx)
WO (1) WO2001019378A2 (xx)
ZA (1) ZA200201249B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
IL154008A0 (en) 2000-07-28 2003-07-31 Hoffmann La Roche New pharmaceutical composition
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
DE10251963A1 (de) * 2002-11-08 2004-05-19 Lts Lohmann Therapie-Systeme Ag Transmucosale pharmazeutische Darreichungsform
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
BR0318167A (pt) * 2003-03-04 2006-02-21 Nostrum Pharmaceuticals Inc formulação de liberação controlada contendo um material hidrofóbico como o agente de liberação controlada
FI20045076A7 (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
BRPI0516772A (pt) * 2004-10-25 2008-09-23 Japan Tobacco Inc formulação sólida com solubilidade e estabilidade melhoradas e método para produção da referida formulação
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
CA2626234A1 (en) * 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
EP1808163A1 (en) * 2005-12-22 2007-07-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
KR100903504B1 (ko) * 2007-05-18 2009-06-17 강태용 비라칸사스 열매 추출물질을 포함하는 기능식품 및 체중 감소제
US20090088424A1 (en) * 2007-08-17 2009-04-02 Ilan Zalit Methods and compositions for controlling the bioavailability of poorly soluble drugs
ATE477820T1 (de) * 2007-09-12 2010-09-15 Mader S R L Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
EP2486805A1 (en) * 2011-02-11 2012-08-15 Puratos N.V. An emulsion whippable at room-temperature
PH12013501815A1 (en) * 2011-04-14 2013-10-14 J Oil Mills Inc Palm-based fractionated oil and fat, and oil and fat composition and food product containing the same
CN102552168B (zh) * 2012-01-31 2013-08-07 杭州华东医药集团生物工程研究所有限公司 一种含有奥利司他的药物组合物及其制备方法
GB2501535A (en) 2012-04-26 2013-10-30 Sony Corp Chrominance Processing in High Efficiency Video Codecs
CA2872644A1 (en) * 2012-05-31 2013-12-05 Repros Therapeutics Inc. Formulations and methods for vaginal delivery of antiprogestins
WO2015063039A1 (en) * 2013-10-28 2015-05-07 Nestec S.A. Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741496A (en) * 1993-09-21 1998-04-21 Laboratoires De Biologie Vegetale Yves Rocher Process for the treatment of skins having dry areas and greasy areas
WO1998034607A1 (en) * 1997-02-05 1998-08-13 F. Hoffmann-La Roche Ag Tetrahydrolipstatin containing compositions
WO2000009123A1 (en) * 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
WO1998024607A1 (en) * 1996-12-04 1998-06-11 Pincott James S Process and apparatus for making crumb rubber from scrap tyres
CN1154505C (zh) 1997-02-05 2004-06-23 弗·哈夫曼-拉罗切有限公司 胃肠道脂酶抑制剂的用途
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
ATE293970T1 (de) 1998-08-14 2005-05-15 Hoffmann La Roche Lipasehemmer enthaltende pharmazeutische zusammensetzungen
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741496A (en) * 1993-09-21 1998-04-21 Laboratoires De Biologie Vegetale Yves Rocher Process for the treatment of skins having dry areas and greasy areas
WO1998034607A1 (en) * 1997-02-05 1998-08-13 F. Hoffmann-La Roche Ag Tetrahydrolipstatin containing compositions
WO2000009123A1 (en) * 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan

Also Published As

Publication number Publication date
RU2248218C2 (ru) 2005-03-20
ATE285783T1 (de) 2005-01-15
EG24225A (en) 2008-11-10
US6703369B1 (en) 2004-03-09
WO2001019378A3 (en) 2001-05-10
BRPI0013940B1 (pt) 2016-06-21
TR200200605T2 (tr) 2002-08-21
KR20020060177A (ko) 2002-07-16
CZ20021277A3 (cs) 2003-04-16
DE60017156T2 (de) 2006-01-05
CZ301844B6 (cs) 2010-07-07
AR025609A1 (es) 2002-12-04
NO328889B1 (no) 2010-06-07
YU13602A (sh) 2006-01-16
NO20021205L (no) 2002-03-12
ES2233444T3 (es) 2005-06-16
KR100523879B1 (ko) 2005-10-26
PL199869B1 (pl) 2008-11-28
MEP90908A (en) 2011-12-20
HRP20020206A2 (en) 2004-04-30
JO2300B1 (en) 2005-09-12
EP1216048A2 (en) 2002-06-26
CN1373659A (zh) 2002-10-09
PL356154A1 (en) 2004-06-14
NO20021205D0 (no) 2002-03-12
MY127430A (en) 2006-11-30
BR0013940A (pt) 2002-05-14
NZ517396A (en) 2003-10-31
CN1197554C (zh) 2005-04-20
HK1049798A1 (en) 2003-05-30
DE60017156D1 (de) 2005-02-03
ME00675B (me) 2011-12-20
GC0000259A (en) 2006-11-01
ZA200201249B (en) 2003-07-30
HK1049798B (zh) 2005-08-05
IL148570A0 (en) 2002-09-12
EP1216048B1 (en) 2004-12-29
SI1216048T1 (en) 2005-06-30
MXPA02002662A (es) 2002-07-30
PT1216048E (pt) 2005-04-29
IL148570A (en) 2007-03-08
MA26817A1 (fr) 2004-12-20
JP2003509373A (ja) 2003-03-11
CA2383036C (en) 2006-01-10
CO5210857A1 (es) 2002-10-30
HU229037B1 (en) 2013-07-29
CA2383036A1 (en) 2001-03-22
RU2002107450A (ru) 2004-01-10
AU7517700A (en) 2001-04-17
JP4217017B2 (ja) 2009-01-28
PE20010661A1 (es) 2001-06-25
RS50373B (sr) 2009-11-10
AU769016B2 (en) 2004-01-15
HUP0202762A3 (en) 2005-04-28
WO2001019378A2 (en) 2001-03-22
HUP0202762A2 (hu) 2003-01-28

Similar Documents

Publication Publication Date Title
HRP20020206B1 (en) Solid lipid formulations
DK1313510T3 (da) Injicerbar farmaceutisk sammensætning til systemisk administration af farmakologisk aktive aktivstoffer indeholdende middelkædede triglycerider
NO975035D0 (no) Fettsyreestere som bioaktive forbindelser
ATE478129T1 (de) Kerzenwachs auf triacylglycerin-basis
AP2000001943A0 (en) Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent.
HUP0101653A3 (en) Fatty acid derivatives of bile acids and bile acid derivatives and pharmaceutical compositions thereof
KR950010875A (ko) 피부외용제
BR9610842A (pt) Composição farmacêutica compreendendo um inibidor de proteinase e um monoglicerídeo
MY161871A (en) Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid mono-ester
DK0825848T3 (da) Translucente collagenformuleringer
WO2003018064A3 (en) Lipophilic drug compositions
IL122942A0 (en) Esters of 1-beta-d-arabinofuranosylcytosine and pharmaceutical compositions containing them
GB2349336B (en) Pesticidal composition based on 2-methoxycarbonyl-4-chlorotrifluoromethanesulphonanilide & an ester of an alkanedicarboxylic, citric or fatty acid
WO2002049582A3 (de) Kosmetische und dermatologische lichtschutzformulierungen mit einem gehalt an benzotriazolderivaten und oberflächenaktiven zitronensäureestern
AR016629A1 (es) Una solucion que comprende un azaesteroide farmaceuticamente activo y un ester de acido graso de glicerol o propilen glicol, composiciones farmaceuticasque comprenden la solucion y capsulas de gelatina rellenas con la composicion farmaceutica.
JPS57126414A (en) Ointment
ECSP003653A (es) Formulaciones solidas de lipido
UY26337A1 (es) Formulaciones de lipidos solidos
DE59812612D1 (de) Enzymatische Herstellung von regioselektiven Fettsäureestern der Ascorbinsäure
ES2177670T3 (es) Composiciones topicas para el cuidado de la piel que contienen esteresde acidos carboxilicos y polioles no oclusivos liquidos.
IL144706A0 (en) Ether type lipid a-1 carboxylic acid analogue and pharmaceutical compositions containing the same
WO2002049642A3 (en) Use of 5-hydroxy and 5-acyloxy-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic acids and their esters as agents useful for healing skin lesions and stimulants of angiogenesis
DK1216048T3 (da) Faste lipidformuleringer, der omfatter en inhibitor af lipaser og en fedtsyreester af polyoler
SE9601483D0 (sv) Beredning av komposition
AU3127095A (en) Determining biodegradability of aspartic acid derivatives, degradable chelants, uses and compositions thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: CHEPLAPHARM ARZNEIMITTEL GMBH, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190905

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20200911